Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves blood coagulation abnormalities and dysfunction of vascular endothelial cells in Otsuka Long-Evans Tokushima fatty rats.
We investigated the effect of highly purified eicosapentaenoic acid ethyl ester (EPA-E) on blood coagulation abnormalities and dysfunction of vascular endothelial cells in spontaneously diabetic Otsuka Long-Evans Tokushima Fatty rats. The animals were treated with either EPA-E or lard at a daily dose of 0.3 g/kg/day for 52 weeks by gavage, and their coagulation/fibrinolytic parameters, platelet aggregation, and functions of the vascular endothelial cells were examined. EPA-E significantly improved coagulation-related parameters including prothrombin time, activated partial thromboplastin time, fibrinogen level, and activities of factor II, V, VII, VIII, IX, X, XI, and XII, and antithrombin III, and fibrinolysis-related parameters including plasminogen, tissue-type plasminogen activator, alpha(2)-plasmin inhibitor, and plasminogen activator inhibitor. It also suppressed ADP- or collagen-induced platelet aggregation and the cholesterol/phospholipid molar ratio in platelet membranes at a dose of 0.3 g/kg. In addition, it significantly increased the migration activity of vascular endothelial cells, and decreased the binding of vascular endothelial cells to vascular endothelial growth factor. In contrast, lard had no effect on hypercoagulation, hypofibrinolysis, and platelet hyperaggregation but significantly aggravated the dysfunction of vascular endothelial cells. These data demonstrate that EPA-E beneficially altered certain factors known to promote thrombosis and atherosclerosis in this animal model.
Mori
Yutaka
Y
Department of Internal Medicine, National Higashi-Utsunomiya Hospital, Tochigi, Japan.
Nobukata
Hidefumi
H
Harada
Tsuyoshi
T
Kasahara
Toshihiko
T
Tajima
Naoko
N
D000818:Animals; D001158:Arteries; D001778:Blood Coagulation Disorders / Q000097:blood / Q000503:physiopathology*; D002465:Cell Movement / Q000187:drug effects; D004334:Drug Administration Schedule; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000302:isolation & purification; D004730:Endothelium, Vascular / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D005342:Fibrinolysis / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000302:isolation & purification; D051381:Rats; D020334:Rats, Inbred OLETF; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D008055:Lipids; D010975:Platelet Aggregation Inhibitors; D042461:Vascular Endothelial Growth Factor A; C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid